Trial Outcomes & Findings for A Study of E7820 in People With Bone Marrow (Myeloid) Cancers (NCT NCT05024994)
NCT ID: NCT05024994
Last Updated: 2026-06-17
Results Overview
To assess the 1 year Overall Survival (OS)
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
12 participants
Primary outcome timeframe
1 year
Results posted on
2026-06-17
Participant Flow
Participant milestones
| Measure |
E7820
Each patient will receive daily administration of E7820. The starting dose for every patient will be 100 mg daily but the dose can subsequently be reduced if excessive toxicity is encountered.
E7820: 100mg of E7820 QD
|
|---|---|
|
Overall Study
STARTED
|
12
|
|
Overall Study
COMPLETED
|
12
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
Baseline characteristics by cohort
| Measure |
E7820
n=12 Participants
Each patient will receive daily administration of E7820. The starting dose for every patient will be 100 mg daily but the dose can subsequently be reduced if excessive toxicity is encountered.
E7820: 100mg of E7820 QD
|
|---|---|
|
Age, Continuous
|
77 years
n=9 Participants
|
|
Sex: Female, Male
Female
|
2 Participants
n=9 Participants
|
|
Sex: Female, Male
Male
|
10 Participants
n=9 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=9 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
11 Participants
n=9 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=9 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=9 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=9 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=9 Participants
|
|
Race (NIH/OMB)
Black or African American
|
1 Participants
n=9 Participants
|
|
Race (NIH/OMB)
White
|
9 Participants
n=9 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=9 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=9 Participants
|
|
Region of Enrollment
United States
|
12 Participants
n=9 Participants
|
PRIMARY outcome
Timeframe: 1 yearTo assess the 1 year Overall Survival (OS)
Outcome measures
| Measure |
E7820
n=12 Participants
Each patient will receive daily administration of E7820. The starting dose for every patient will be 100 mg daily but the dose can subsequently be reduced if excessive toxicity is encountered.
E7820: 100mg of E7820 QD
|
|---|---|
|
Median Overall Survival
|
3.8 months
Interval 1.5 to 12.0
|
Adverse Events
E7820
Serious events: 9 serious events
Other events: 10 other events
Deaths: 5 deaths
Serious adverse events
| Measure |
E7820
n=12 participants at risk
Each patient will receive daily administration of E7820. The starting dose for every patient will be 100 mg daily but the dose can subsequently be reduced if excessive toxicity is encountered.
E7820: 100mg of E7820 QD
|
|---|---|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
8.3%
1/12 • 1 year
|
|
Infections and infestations
Enterocolitis infectious
|
8.3%
1/12 • 1 year
|
|
General disorders
Fever
|
8.3%
1/12 • 1 year
|
|
General disorders
Multi-organ failure
|
8.3%
1/12 • 1 year
|
|
Blood and lymphatic system disorders
Anemia
|
8.3%
1/12 • 1 year
|
|
Gastrointestinal disorders
Dysphagia
|
8.3%
1/12 • 1 year
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
8.3%
1/12 • 1 year
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
8.3%
1/12 • 1 year
|
|
Renal and urinary disorders
Urinary tract pain
|
8.3%
1/12 • 1 year
|
|
Reproductive system and breast disorders
Vaginal discharge
|
8.3%
1/12 • 1 year
|
|
Cardiac disorders
Cardiac arrest
|
8.3%
1/12 • 1 year
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
16.7%
2/12 • 1 year
|
|
Infections and infestations
Sepsis
|
16.7%
2/12 • 1 year
|
|
General disorders
Death NOS
|
25.0%
3/12 • 1 year
|
|
Nervous system disorders
Intercranial hemorrhage
|
8.3%
1/12 • 1 year
|
|
Vascular disorders
Hematoma
|
8.3%
1/12 • 1 year
|
|
Nervous system disorders
Nervous system disorders - Other, specify
|
8.3%
1/12 • 1 year
|
|
Infections and infestations
Lung infection
|
25.0%
3/12 • 1 year
|
|
Nervous system disorders
Presyncope
|
8.3%
1/12 • 1 year
|
|
Vascular disorders
Hypotension
|
8.3%
1/12 • 1 year
|
|
General disorders
Disease progression
|
8.3%
1/12 • 1 year
|
Other adverse events
| Measure |
E7820
n=12 participants at risk
Each patient will receive daily administration of E7820. The starting dose for every patient will be 100 mg daily but the dose can subsequently be reduced if excessive toxicity is encountered.
E7820: 100mg of E7820 QD
|
|---|---|
|
Blood and lymphatic system disorders
Anemia
|
16.7%
2/12 • 1 year
|
|
Blood and lymphatic system disorders
Neutropenia
|
16.7%
2/12 • 1 year
|
|
Gastrointestinal disorders
Diarrhea
|
50.0%
6/12 • 1 year
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
33.3%
4/12 • 1 year
|
|
General disorders
Non-cardiac chest pain
|
25.0%
3/12 • 1 year
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
25.0%
3/12 • 1 year
|
|
Injury, poisoning and procedural complications
Fall
|
25.0%
3/12 • 1 year
|
|
Gastrointestinal disorders
Nausea
|
25.0%
3/12 • 1 year
|
|
Gastrointestinal disorders
Abdominal pain
|
16.7%
2/12 • 1 year
|
|
General disorders
Fever
|
16.7%
2/12 • 1 year
|
|
Vascular disorders
Hematoma
|
16.7%
2/12 • 1 year
|
|
Infections and infestations
Lung infection
|
16.7%
2/12 • 1 year
|
|
Nervous system disorders
Dizziness
|
16.7%
2/12 • 1 year
|
|
General disorders
Fatigue
|
16.7%
2/12 • 1 year
|
|
Gastrointestinal disorders
Flatulence
|
16.7%
2/12 • 1 year
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
16.7%
2/12 • 1 year
|
|
Infections and infestations
Sepsis
|
16.7%
2/12 • 1 year
|
|
General disorders
Pain
|
16.7%
2/12 • 1 year
|
Additional Information
Dr. Eytan Stein, MD
Memorial Sloan Kettering Cancer Center
Phone: 646-608-3749
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place